Table 3.

Multivariate analysis (N = 151).

Characteristics	Overall survival	Progression-free survival	Locoregional control	Distant metastasis
	HR (95% CI) p-value	HR (95% CI) p-value	HR (95% CI) p-value	HR (95% CI) p-value
Unresectable disease	2.008 (1.156–3.487)	NS	NS	NS
	0.013
Stage IV disease	7.229 (0.993–52.638)	4.387 (1.376–13.950)	4.078 (1.266–13.134)	NS
	0.051	0.012	0.018
Non-oropharyngeal cancer	3.574 (2.018–6.332)	2.802 (1.742–2.509)	2.516 (1.552–4.159)	NS
	0.000	0.000	0.000
Hypopharyngeal cancer	NS	NS	NS	3.099 (1.264–7.600)
				0.013
RT dosage <70 Gy	8.001 (4.278–14.63)	4.952 (2.802–8.751)	6.392 (3.547–11.521)	NS
	0.000	0.000	0.000
Accumulated dose of cisplatin during radiotherapy <150 mg/m [2]	NS	1.922 (1.200–3.079)	2.641 (1.613–4.325)	NS
		0.002	0.000
ECOG Performance status = 2	NS	NS	NS	4.946 (1.448–16.891)
				0.011
Treatment arm	NS	NS	NS	NS

Abbreviations: ECOG, Eastern Cooperative Oncology Group; CI, confidence interval; HR, hazard ratio; NS, not significant.